✦ LIBER ✦

Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting

✍ Scribed by Suzanna M. Zick; Mack T. Ruffin; Julia Lee; Daniel P. Normolle; Rivka Siden; Sara Alrawi; Dean E. Brenner

Publisher: Springer-Verlag
Year: 2008
Tongue: English
Weight: 194 KB
Volume: 17
Category: Article
ISSN: 0941-4355
DOI: 10.1007/s00520-008-0528-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I-trial of clebopride, a new antie

Phase I-trial of clebopride, a new antiemetic, in chemotherapy — induced nausea and vomiting

✍ H. J. Lenz; U. Schuler; W. Hicking; G. Ehninger 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 109 KB

A phase II trial of olanzapine for the p

A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier Oncology Group study

✍ Rudolph M. Navari; Lawrence H. Einhorn; Steven D. Passik; Patrick J. Loehrer; Cy 📂 Article 📅 2005 🏛 Springer-Verlag 🌐 English ⚖ 97 KB

A phase II trial of olanzapine, dexameth

A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study

✍ Rudolph M. Navari; Lawrence H. Einhorn; Patrick J. Loehrer; Steven D. Passik; Ja 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 165 KB

Palonosetron for the prevention of chemo

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study

✍ Antonio Rozzi; Chiara Nardoni; Michela Corona; Maria Rosa Restuccia; Alessandra 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 114 KB

Granisetron is equivalent to ondansetron

Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting : Results of a meta-analysis of randomized controlled trials

✍ Auro del Giglio; Heloisa P. Soares; Carla Caparroz; Paulo C. Castro 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 2 views

A phase I study of a new 5HT3-receptor a

A phase I study of a new 5HT3-receptor antagonist, BRL43694A, an agent for the prevention of chemotherapy-induced nausea and vomiting

✍ Geoffrey Falkson; Adriaan J. Zyl 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 370 KB

In a phase I study of BRL43694A, a 5HT3-receptor antagonist, a single dose of 40 micrograms/kg was given to 24 patients. All patients received cytostatic treatment expected to cause nausea and vomiting. During the first 24 h, 12 patients were completely protected from nausea and vomiting, 4 experien